Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free MLSS Stock Alerts

Milestone Scientific (MLSS) Financials

Milestone Scientific logo
$0.42 0.00 (-1.08%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$0.42 +0.00 (+0.24%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Milestone Scientific

Annual Income Statements for Milestone Scientific

This table shows Milestone Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5.47 -5.95 -5.19 -7.43 -7.52 -7.34 -6.82 -8.71 -6.93 -4.71 -5.72
Consolidated Net Income / (Loss)		 -5.54 -7.29 -5.37 -7.69 -7.58 -7.39 -6.88 -8.77 -6.98 -4.71 -5.72
Net Income / (Loss) Continuing Operations		 -3.09 -6.50 -5.25 -8.02 -7.58 -7.49 -6.88 -8.77 -6.98 -4.71 -5.72
Total Pre-Tax Income 		-3.06 -6.52 -5.23 -8.00 -7.64 -7.47 -7.12 -8.77 -6.98 -4.71 -5.72
Total Operating Income		 -3.06 -6.51 -5.23 -8.00 -4.00 -7.45 -7.38 -8.83 -7.11 -6.76 -5.70
Total Gross Profit		 6.44 6.31 6.97 4.43 5.72 3.62 6.31 4.90 6.79 6.43 6.41
Total Revenue		 9.49 10 11 9.62 8.37 5.44 10 8.81 9.83 8.63 8.97
Operating Revenue		 9.49 10 11 9.62 8.37 5.44 10 8.81 9.83 8.63 8.97
Total Cost of Revenue		 3.05 4.18 4.31 5.19 2.66 1.82 3.99 3.91 3.03 2.20 2.57
Operating Cost of Revenue		 3.05 4.18 4.31 5.19 2.66 1.82 3.99 3.91 3.03 2.20 2.57
Total Operating Expenses		 9.50 13 12 12 9.72 11 14 14 14 13 12
Selling, General & Admin Expense		 9.40 12 12 11 9.53 11 13 13 13 12 12
Research & Development Expense		 0.10 1.27 0.27 0.25 0.19 0.31 0.88 1.15 0.70 0.86 0.45
Depreciation Expense		 - - - - - 0.10 0.07 0.06 0.06 0.04 0.08
Total Other Income / (Expense), net		 -0.00 -0.00 0.00 0.00 -3.64 -0.02 0.26 0.05 0.13 2.04 -0.03
Interest & Investment Income		 0.00 0.00 0.13 -0.33 - - - - - 0.06 -0.03
Income Tax Expense		 0.04 -0.02 0.02 0.02 0.02 0.02 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($0.26) ($0.22) ($0.16) ($0.21) ($0.16) ($0.12) ($0.10) ($0.12) ($0.10) ($0.06) ($0.07)
Weighted Average Basic Shares Outstanding		 21.43M 26.97M 32.70M 35.30M 45.74M 63.06M 68.83M 70.61M 72.78M 79.79M 82.06M
Diluted Earnings per Share		 ($0.26) ($0.22) ($0.16) ($0.21) ($0.16) ($0.12) - - - ($0.06) ($0.07)
Weighted Average Diluted Shares Outstanding		 21.43M 26.97M 32.70M 35.30M 45.74M 63.06M 68.12M 70.00M 76.60M 79.79M 82.06M
Weighted Average Basic & Diluted Shares Outstanding		 21M 30.68M 33.16M 40.86M 49.41M 66.56M 68.12M 70.00M 76.60M - 80.45M

Quarterly Income Statements for Milestone Scientific

This table shows Milestone Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -1.47 -1.94 -1.44 0.22 -1.46 -2.04 -1.99 -1.48 -1.15 -1.09 -0.84
Consolidated Net Income / (Loss)		 -1.48 -1.96 -1.44 0.22 -1.46 -2.04 -1.99 -1.48 -1.15 -1.09 -0.84
Net Income / (Loss) Continuing Operations		 -1.48 -1.96 -1.44 0.22 -1.46 -2.04 -1.99 -1.48 -1.15 -1.09 -0.84
Total Pre-Tax Income 		-1.48 -1.96 -1.44 0.22 -1.46 -2.04 -1.99 -1.48 -1.15 -1.09 -0.84
Total Operating Income		 -1.51 -1.98 -1.47 -1.78 -1.47 -2.04 -2.00 -1.48 -1.13 -1.08 -0.83
Total Gross Profit		 1.50 1.51 1.68 1.41 1.84 1.51 1.65 1.62 1.64 1.50 1.56
Total Revenue		 2.06 2.26 2.25 1.85 2.51 2.01 2.23 2.32 2.36 2.06 2.16
Operating Revenue		 2.06 2.26 2.25 1.85 2.51 2.01 2.23 2.32 2.36 2.06 2.16
Total Cost of Revenue		 0.56 0.75 0.57 0.44 0.68 0.50 0.58 0.71 0.72 0.56 0.60
Operating Cost of Revenue		 0.56 0.75 0.57 0.44 0.68 0.50 0.58 0.71 0.72 0.56 0.60
Total Operating Expenses		 3.01 3.49 3.14 3.19 3.31 3.55 3.65 3.10 2.78 2.58 2.39
Selling, General & Admin Expense		 2.82 3.30 3.04 2.87 3.06 3.33 3.26 3.03 2.74 2.55 2.37
Research & Development Expense		 0.17 0.18 0.09 0.31 0.23 0.22 0.37 0.05 0.02 0.01 0.00
Depreciation Expense		 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02
Total Other Income / (Expense), net		 0.03 0.02 0.02 2.00 0.01 0.01 0.00 0.00 -0.02 -0.01 -0.01
Interest & Investment Income		 - - - - 0.01 - 0.00 - -0.02 - -0.01
Income Tax Expense		 - - - 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.02) ($0.03) ($0.02) $0.00 ($0.02) ($0.02) ($0.02) ($0.02) ($0.01) ($0.02) ($0.01)
Weighted Average Basic Shares Outstanding		 73.73M 72.78M 79.74M 79.97M 79.97M 79.79M 81.85M 82.05M 82.32M 82.06M 85.04M
Diluted Earnings per Share		 - - - - ($0.02) - ($0.02) - ($0.01) - ($0.01)
Weighted Average Diluted Shares Outstanding		 71.05M 76.60M 77.23M 77.29M 79.97M 79.79M 81.85M 78.56M 82.32M 82.06M 85.04M
Weighted Average Basic & Diluted Shares Outstanding		 71.05M 76.60M 77.23M 77.29M 77.89M 0.00 78.48M 78.56M 78.63M 80.45M 88.08M

Annual Cash Flow Statements for Milestone Scientific

This table details how cash moves in and out of Milestone Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -6.17 -0.59 -0.97 -1.89 0.77 13 0.54 -6.05 -5.74 0.28 -2.15
Net Cash From Operating Activities		 -1.56 -5.40 -1.23 -1.63 -1.78 -6.98 -4.03 -6.03 -5.33 -2.92 -2.92
Net Cash From Continuing Operating Activities		 -2.95 -5.40 -1.23 -1.63 -1.78 -6.98 -4.03 -6.03 -5.33 -2.92 -2.92
Net Income / (Loss) Continuing Operations		 -6.68 -7.29 -5.37 -7.69 -7.58 -7.39 -6.88 -8.77 -6.98 -4.71 -5.72
Consolidated Net Income / (Loss)		 -6.68 -7.29 -5.37 -7.69 -7.58 -7.39 -6.88 -8.77 -6.98 -4.71 -5.72
Depreciation Expense		 0.03 0.09 0.06 0.07 0.05 0.04 0.02 0.01 0.01 0.01 0.01
Amortization Expense		 0.07 0.07 0.51 0.81 0.05 0.05 0.13 0.13 0.14 0.13 0.18
Non-Cash Adjustments To Reconcile Net Income		 5.57 3.16 1.00 2.10 -2.01 2.42 0.88 2.81 2.78 2.19 2.61
Changes in Operating Assets and Liabilities, net		 -0.55 -1.43 2.57 3.08 -0.48 -2.11 1.82 -0.21 -1.27 -0.54 0.01
Net Cash From Investing Activities		 -3.73 0.01 -0.20 -0.02 -0.01 -0.02 -0.02 -0.01 -2.97 2.97 -0.02
Net Cash From Continuing Investing Activities		 -3.73 0.01 -0.20 -0.02 -0.01 -0.02 -0.02 -0.01 -2.97 2.97 -0.02
Purchase of Property, Plant & Equipment		 -0.07 -0.02 -0.01 -0.01 -0.01 -0.02 -0.02 -0.01 -0.00 -0.01 -0.02
Sale and/or Maturity of Investments		 - - - - - - - 0.00 4.97 2.98 0.00
Net Cash From Financing Activities		 0.50 4.80 0.46 -0.25 2.56 20 4.59 -0.01 2.56 0.23 0.79
Net Cash From Continuing Financing Activities		 0.50 4.80 0.46 -0.25 2.56 20 4.59 -0.01 2.56 0.23 0.79
Issuance of Debt		 - - - - 0.00 0.28 - - - 0.00 0.80
Issuance of Common Equity		 0.50 4.80 0.15 0.00 2.22 18 - 0.00 2.57 0.19 0.00
Other Financing Activities, net		 - - 0.31 -0.25 0.34 1.39 4.59 -0.01 -0.01 0.04 -0.01

Quarterly Cash Flow Statements for Milestone Scientific

This table details how cash moves in and out of Milestone Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.53 0.81 1.03 1.75 -0.98 -1.52 -1.01 -0.97 0.07 -0.23 0.08
Net Cash From Operating Activities		 -1.05 -1.25 -1.22 0.78 -0.97 -1.51 -1.01 -1.76 0.08 -0.23 0.09
Net Cash From Continuing Operating Activities		 -1.05 -1.25 -1.22 0.78 -0.97 -1.51 -1.01 -1.76 0.08 -0.23 0.09
Net Income / (Loss) Continuing Operations		 -1.48 -1.96 -1.44 0.22 -1.46 -2.04 -1.99 -1.48 -1.15 -1.09 -0.84
Consolidated Net Income / (Loss)		 -1.48 -1.96 -1.44 0.22 -1.46 -2.04 -1.99 -1.48 -1.15 -1.09 -0.84
Depreciation Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Amortization Expense		 0.04 0.03 0.03 0.03 0.03 0.03 0.04 0.05 0.04 0.05 0.05
Non-Cash Adjustments To Reconcile Net Income		 0.45 0.97 0.58 0.48 0.87 0.26 0.93 0.12 0.09 1.47 0.29
Changes in Operating Assets and Liabilities, net		 -0.07 -0.29 -0.39 0.05 -0.42 0.23 0.01 -0.45 1.11 -0.65 0.59
Net Cash From Investing Activities		 -0.48 -0.51 2.00 0.97 - -0.00 -0.00 -0.00 -0.01 -0.00 -0.00
Net Cash From Continuing Investing Activities		 -0.48 -0.51 2.00 0.97 - -0.00 -0.00 -0.00 -0.01 -0.00 -0.00
Purchase of Property, Plant & Equipment		 0.00 -0.00 0.00 -0.01 - -0.00 -0.00 -0.00 -0.01 -0.00 -0.00
Net Cash From Financing Activities		 -0.00 2.57 0.24 -0.00 -0.00 -0.00 -0.00 0.80 -0.00 -0.00 -0.00
Net Cash From Continuing Financing Activities		 -0.00 2.57 0.24 -0.00 -0.00 -0.00 -0.00 0.80 -0.00 -0.00 -0.00
Other Financing Activities, net		 -0.00 -0.00 0.05 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00

Annual Balance Sheets for Milestone Scientific

This table presents Milestone Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 13 14 16 6.40 6.56 20 20 14 11 9.80 7.81
Total Current Assets		 12 13 12 5.86 6.08 19 19 13 11 9.29 7.48
Cash & Equivalents		 4.19 3.60 2.64 0.74 1.52 14 15 8.72 2.98 3.26 1.11
Accounts Receivable		 1.85 3.53 3.26 2.08 1.71 1.08 0.94 0.69 0.31 0.48 0.71
Inventories, net		 5.47 5.30 4.08 2.57 2.33 2.83 2.85 3.12 4.01 4.99 5.19
Prepaid Expenses		 0.30 0.29 0.44 0.41 0.52 0.42 0.38 0.44 0.52 0.56 0.47
Plant, Property, & Equipment, net		 0.24 0.16 0.14 0.08 0.04 0.03 0.02 0.02 0.01 0.01 0.02
Total Noncurrent Assets		 0.73 0.68 3.47 0.46 0.43 0.99 0.85 0.71 0.57 0.50 0.31
Noncurrent Note & Lease Receivables		 - 0.00 0.65 - - - 0.03 0.02 0.01 0.07 0.06
Intangible Assets		 0.72 0.66 2.79 0.44 0.38 0.33 0.28 0.23 0.18 0.15 0.08
Other Noncurrent Operating Assets		 0.02 0.02 0.03 0.03 0.05 0.66 0.55 0.47 0.38 0.28 0.17
Total Liabilities & Shareholders' Equity		 13 14 16 6.40 6.56 20 20 14 11 9.80 7.81
Total Liabilities		 3.64 5.65 8.13 4.87 4.93 3.46 3.59 3.70 3.36 3.96 4.99
Total Current Liabilities		 3.64 5.65 6.73 4.87 4.93 2.88 3.10 3.30 3.08 3.74 4.13
Accounts Payable		 2.09 2.58 1.96 2.87 2.74 0.87 1.18 1.91 1.10 1.51 2.79
Accrued Expenses		 1.56 1.44 2.29 1.48 1.83 1.41 1.83 1.29 1.65 2.10 1.18
Other Current Liabilities		 - - - 0.00 0.02 0.08 0.09 0.10 0.11 0.13 0.16
Total Noncurrent Liabilities		 0.00 0.00 1.40 0.00 0.00 0.59 0.50 0.40 0.28 0.22 0.86
Long-Term Debt		 - - - - - - - - - 0.00 0.80
Other Noncurrent Operating Liabilities		 - 0.00 1.40 - 0.00 0.59 0.50 0.40 0.28 0.22 0.06
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.17 8.54 7.50 1.53 1.63 16 16 10 8.01 5.83 2.81
Total Preferred & Common Equity		 10 8.50 7.24 1.54 1.70 16 16 10 8.01 5.83 2.81
Total Common Equity		 10 8.50 7.24 1.54 1.70 16 16 10 8.01 5.83 2.81
Common Stock		 79 83 87 88 96 118 125 128 132 135 137
Retained Earnings		 -67 -73 -79 -86 -94 -101 -108 -116 -123 -128 -134
Treasury Stock		 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91

Quarterly Balance Sheets for Milestone Scientific

This table presents Milestone Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 11 11 12 11 9.09 8.05 8.49 7.96
Total Current Assets		 9.97 11 11 11 8.62 7.63 8.11 7.35
Cash & Equivalents		 2.17 4.01 5.75 4.78 2.25 1.27 1.35 1.19
Accounts Receivable		 0.59 0.66 0.39 0.55 0.52 0.69 0.72 0.58
Inventories, net		 4.18 4.28 4.58 4.72 5.10 5.03 5.54 4.90
Prepaid Expenses		 0.58 0.86 0.77 0.65 0.75 0.64 0.51 0.68
Plant, Property, & Equipment, net		 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02
Total Noncurrent Assets		 0.60 0.53 0.50 0.47 0.45 0.41 0.36 0.59
Noncurrent Note & Lease Receivables		 0.01 0.01 0.00 0.00 0.06 0.05 0.06 0.05
Intangible Assets		 0.19 0.17 0.16 0.16 0.13 0.11 0.10 0.06
Other Noncurrent Operating Assets		 0.40 0.35 0.33 0.31 0.26 0.24 0.20 0.48
Total Liabilities & Shareholders' Equity		 11 11 12 11 9.09 8.05 8.49 7.96
Total Liabilities		 3.59 3.89 4.05 3.95 4.63 4.71 5.94 5.68
Total Current Liabilities		 3.28 3.64 3.83 3.76 4.44 3.77 5.03 4.86
Accounts Payable		 1.79 1.89 2.22 1.88 2.68 1.96 3.04 3.26
Accrued Expenses		 1.38 1.41 1.28 1.55 1.63 1.67 1.84 1.43
Other Current Liabilities		 0.11 0.12 0.12 0.12 0.14 0.14 0.15 0.16
Total Noncurrent Liabilities		 0.31 0.25 0.23 0.20 0.18 0.94 0.90 0.82
Long-Term Debt		 - - - - - 0.80 0.80 0.80
Other Noncurrent Operating Liabilities		 0.31 0.25 0.23 0.20 0.18 0.14 0.10 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 6.99 7.46 7.95 7.22 4.46 3.34 2.55 2.28
Total Preferred & Common Equity		 7.25 7.46 7.95 7.22 4.46 3.34 2.55 2.28
Total Common Equity		 7.25 7.46 7.95 7.22 4.46 3.34 2.55 2.28
Common Stock		 130 133 133 134 135 136 136 138
Retained Earnings		 -121 -125 -125 -126 -130 -132 -133 -135
Treasury Stock		 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91 -0.91

Annual Metrics And Ratios for Milestone Scientific

This table displays calculated financial ratios and metrics derived from Milestone Scientific's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 21,478,248.00 28,054,670.00 32,989,724.00 33,825,701.00 48,884,752.00 63,693,469.00 67,845,930.00 69,795,330.00 71,048,241.00 77,892,083.00 78,628,913.00
DEI Adjusted Shares Outstanding		 21,478,248.00 28,054,670.00 32,989,724.00 33,825,701.00 48,884,752.00 63,693,469.00 67,845,930.00 69,795,330.00 71,048,241.00 77,892,083.00 78,628,913.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.25 -0.21 -0.16 -0.22 -0.15 -0.12 -0.10 -0.12 -0.10 -0.06 -0.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -8.14% 10.43% 7.63% -14.71% -12.97% -35.07% 89.52% -14.54% 11.60% -12.19% 3.99%
EBITDA Growth		 -326.99% -114.38% 24.69% -41.97% -11.02% 2.48% 1.71% -20.08% 19.89% 33.31% -18.80%
EBIT Growth		 -287.52% -112.90% 17.78% -43.23% 0.42% 2.51% 1.00% -19.64% 19.50% 32.82% -19.33%
NOPAT Growth		 -286.84% -113.10% 19.64% -52.82% 50.01% -86.37% 1.00% -19.64% 19.50% 4.92% 15.69%
Net Income Growth		 -224.45% -31.67% 26.39% -43.25% 1.45% 2.53% 6.93% -27.58% 20.43% 32.48% -21.40%
EPS Growth		 -225.00% 15.38% 27.27% -31.25% 23.81% 25.00% 0.00% 0.00% 0.00% 0.00% -16.67%
Operating Cash Flow Growth		 -222.99% -245.84% 77.23% -32.43% -9.29% -292.57% 42.25% -49.54% 11.70% 45.18% 0.11%
Free Cash Flow Firm Growth		 -558.07% -23.29% 20.83% 57.68% -39.87% -241.53% 38.65% -35.06% 1.06% 15.50% 22.24%
Invested Capital Growth		 45.18% -0.42% -1.43% -83.86% -85.68% 1,821.45% -32.80% -11.02% 75.98% 13.31% -2.90%
Revenue Q/Q Growth		 -1.82% -9.81% 8.26% 19.21% -14.89% -1.61% 6.56% -6.43% 0.20% -2.78% 0.50%
EBITDA Q/Q Growth		 8.13% -24.14% 8.11% 21.41% -74.79% -0.98% -4.88% -5.72% 0.46% 29.30% 15.08%
EBIT Q/Q Growth		 7.90% -23.78% 2.22% 22.01% -72.98% -0.93% -4.92% -5.67% 0.49% 28.69% 14.46%
NOPAT Q/Q Growth		 8.07% -23.69% 4.41% 17.67% -37.98% -0.93% -4.92% -5.67% 0.49% -0.94% 14.46%
Net Income Q/Q Growth		 -10.74% -3.40% 9.09% 19.57% -62.73% 19.49% -0.62% -10.71% 0.43% -1.70% 14.17%
EPS Q/Q Growth		 -8.33% 4.35% 11.11% 22.22% -77.78% 29.41% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 37.30% -181.48% 56.70% -0.08% -88.05% -1.97% 5.49% -12.81% -3.02% -10.01% 30.59%
Free Cash Flow Firm Q/Q Growth		 33.28% -270.96% 37.11% -133.13% -135.25% 0.96% 6.93% -5.99% 0.77% -1.17% 2.31%
Invested Capital Q/Q Growth		 -32.70% 0.72% -28.27% 24.35% 122.77% 29.15% -5.61% -5.70% -4.20% -3.20% 24.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 67.88% 60.16% 61.77% 46.05% 68.28% 66.60% 61.25% 55.65% 69.12% 74.56% 71.40%
EBITDA Margin		 -31.24% -60.63% -42.43% -70.62% -90.09% -135.31% -70.17% -98.61% -70.78% -53.76% -61.41%
Operating Margin		 -32.20% -62.14% -46.40% -83.14% -47.75% -137.08% -71.60% -100.24% -72.31% -78.30% -63.48%
EBIT Margin		 -32.26% -62.19% -47.51% -79.78% -91.29% -137.08% -71.60% -100.24% -72.31% -55.32% -63.48%
Profit (Net Income) Margin		 -58.37% -69.59% -47.59% -79.94% -90.52% -135.89% -66.73% -99.62% -71.04% -54.62% -63.76%
Tax Burden Percent		 181.15% 111.92% 102.67% 96.16% 99.17% 98.90% 96.60% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.87% 99.98% 97.58% 104.20% 99.98% 100.24% 96.48% 99.38% 98.23% 98.74% 100.45%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -51.14% -92.22% -74.79% -198.27% -624.04% -459.34% -286.13% -450.68% -279.20% -195.17% -157.16%
ROIC Less NNEP Spread (ROIC-NNEP)		 -8.21% -22.22% -20.12% -74.48% -200.89% -431.25% -274.20% -428.59% -251.44% -195.53% -60.00%
Return on Net Nonoperating Assets (RNNOA)		 5.37% 9.81% 7.83% 27.89% 143.80% 376.02% 243.58% 383.77% 201.72% 127.08% 24.78%
Return on Equity (ROE)		 -45.77% -82.42% -66.96% -170.38% -480.24% -83.32% -42.55% -66.91% -77.48% -68.09% -132.38%
Cash Return on Invested Capital (CROIC)		 -88.00% -91.80% -73.36% -53.84% -474.14% -639.55% -246.89% -439.02% -334.27% -207.65% -154.22%
Operating Return on Assets (OROA)		 -20.22% -48.31% -35.96% -69.70% -118.00% -57.05% -37.47% -52.68% -56.68% -45.10% -64.72%
Return on Assets (ROA)		 -36.58% -54.05% -36.02% -69.83% -117.00% -56.56% -34.92% -52.36% -55.68% -44.53% -65.01%
Return on Common Equity (ROCE)		 -47.18% -87.57% -65.74% -165.75% -492.21% -84.08% -42.87% -67.86% -78.43% -68.09% -132.38%
Return on Equity Simple (ROE_SIMPLE)		 -53.74% -85.82% -74.13% -499.59% -446.97% -45.61% -42.01% -85.79% -87.13% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.14 -4.56 -3.66 -5.60 -2.80 -5.22 -5.16 -6.18 -4.97 -4.73 -3.99
NOPAT Margin		 -22.54% -43.50% -32.48% -58.19% -33.43% -95.95% -50.12% -70.17% -50.62% -54.81% -44.44%
Net Nonoperating Expense Percent (NNEP)		 -42.93% -70.00% -54.67% -123.79% -423.15% -28.09% -11.92% -22.09% -27.76% 0.36% -97.16%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -62.08% -81.09% -110.38%
Cost of Revenue to Revenue		 32.12% 39.84% 38.23% 53.95% 31.72% 33.40% 38.75% 44.35% 30.88% 25.44% 28.60%
SG&A Expenses to Revenue		 99.03% 110.19% 105.75% 110.63% 113.77% 196.25% 123.62% 142.11% 133.66% 142.47% 129.00%
R&D to Revenue		 1.06% 12.12% 2.42% 2.55% 2.27% 5.66% 8.52% 13.06% 7.14% 9.95% 5.01%
Operating Expenses to Revenue		 100.09% 122.31% 108.17% 129.19% 116.04% 203.68% 132.86% 155.90% 141.43% 152.86% 134.88%
Earnings before Interest and Taxes (EBIT)		 -3.06 -6.52 -5.36 -7.68 -7.64 -7.45 -7.38 -8.83 -7.11 -4.77 -5.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.96 -6.36 -4.79 -6.80 -7.54 -7.36 -7.23 -8.68 -6.96 -4.64 -5.51
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.90 4.62 5.38 7.29 40.07 8.33 8.54 3.28 6.12 12.82 7.63
Price to Tangible Book Value (P/TBV)		 5.26 5.01 8.75 10.16 51.73 8.51 8.69 3.35 6.26 13.15 7.85
Price to Revenue (P/Rev)		 5.32 3.75 3.45 1.17 8.11 24.83 13.56 3.80 4.99 8.66 2.39
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 9.11 7.24 7.52 13.33 590.58 56.03 86.04 19.03 18.95 27.78 8.46
Enterprise Value to Revenue (EV/Rev)		 4.76 3.41 3.24 1.09 7.92 22.25 12.12 2.79 4.38 8.29 2.36
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.28
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28
Financial Leverage		 -0.65 -0.44 -0.39 -0.37 -0.72 -0.87 -0.89 -0.90 -0.80 -0.65 -0.41
Leverage Ratio		 1.25 1.52 1.86 2.44 4.10 1.47 1.22 1.28 1.39 1.53 2.04
Compound Leverage Factor		 1.25 1.52 1.81 2.54 4.10 1.48 1.18 1.27 1.37 1.51 2.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.69% 0.00% 0.00% 0.00% 0.00% 22.14%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 1.69% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 22.14%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -12.47% 0.42% 3.42% -0.75% -4.13% -0.58% -0.94% -2.19% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 112.47% 99.58% 96.58% 100.75% 104.13% 98.89% 100.94% 102.19% 100.00% 100.00% 77.86%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.04 0.00 0.00 0.00 0.00 -0.15
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.90 0.00 0.00 0.00 0.00 0.06
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.15
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.05 0.00 0.00 0.00 0.00 -0.20
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 2.67 0.00 0.00 0.00 0.00 0.08
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.20
Altman Z-Score		 1.66 -3.20 -4.17 -19.70 -14.06 16.15 15.97 -7.09 -6.81 -7.03 -22.16
Noncontrolling Interest Sharing Ratio		 -3.09% -6.25% 1.83% 2.72% -2.49% -0.91% -0.76% -1.42% -1.22% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.25 2.36 1.79 1.20 1.23 6.45 6.11 3.93 3.51 2.48 1.81
Quick Ratio		 1.66 1.26 0.95 0.58 0.65 5.32 5.07 2.85 2.04 1.00 0.44
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.68 -4.54 -3.59 -1.52 -2.13 -7.26 -4.46 -6.02 -5.96 -5.03 -3.91
Operating Cash Flow to CapEx		 -2,309.81% -35,183.66% -20,463.28% -21,998.46% -17,943.61% -32,581.99% -26,556.48% -70,739.96% -109,119.63% -28,841.12% -19,284.76%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -401.75 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -386.31 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -387.50 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.63 0.78 0.76 0.87 1.29 0.42 0.52 0.53 0.78 0.82 1.02
Accounts Receivable Turnover		 5.59 3.90 3.32 3.60 4.42 3.90 10.18 10.76 19.53 21.90 15.19
Inventory Turnover		 0.70 0.77 0.92 1.56 1.08 0.70 1.40 1.31 0.85 0.49 0.50
Fixed Asset Turnover		 58.45 53.08 75.02 85.79 131.33 143.64 378.56 420.74 697.72 752.23 558.88
Accounts Payable Turnover		 1.72 1.79 1.90 2.15 0.95 1.01 3.91 2.53 2.02 1.68 1.19
Days Sales Outstanding (DSO)		 65.25 93.65 109.80 101.27 82.57 93.69 35.84 33.93 18.69 16.66 24.03
Days Inventory Outstanding (DIO)		 520.36 471.02 396.95 233.67 336.74 519.14 259.85 278.93 428.61 748.03 723.82
Days Payable Outstanding (DPO)		 212.07 203.87 192.11 169.91 385.28 362.43 93.44 144.06 180.79 217.37 306.11
Cash Conversion Cycle (CCC)		 373.54 360.80 314.65 165.04 34.04 250.40 202.25 168.80 266.51 547.32 441.74
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 4.95 4.93 4.86 0.78 0.11 2.16 1.45 1.29 2.27 2.57 2.50
Invested Capital Turnover		 2.27 2.12 2.30 3.41 18.67 4.79 5.71 6.42 5.52 3.56 3.54
Increase / (Decrease) in Invested Capital		 1.54 -0.02 -0.07 -4.08 -0.67 2.05 -0.71 -0.16 0.98 0.30 -0.07
Enterprise Value (EV)		 45 36 37 10 66 121 125 25 43 72 21
Market Capitalization		 50 39 39 11 68 135 140 34 49 75 21
Book Value per Share		 $0.48 $0.30 $0.22 $0.05 $0.03 $0.25 $0.24 $0.15 $0.11 $0.07 $0.04
Tangible Book Value per Share		 $0.45 $0.28 $0.14 $0.03 $0.03 $0.25 $0.24 $0.14 $0.11 $0.07 $0.03
Total Capital		 9.17 8.54 7.50 1.53 1.63 16 16 10 8.01 5.83 3.61
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.28 0.00 0.00 0.00 0.00 0.80
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.80
Net Debt		 -4.19 -3.60 -2.64 -0.74 -1.52 -14 -15 -8.72 -5.95 -3.26 -0.31
Capital Expenditures (CapEx)		 0.07 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.01 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.99 4.10 2.66 0.24 -0.37 1.73 1.07 0.96 1.76 2.28 2.23
Debt-free Net Working Capital (DFNWC)		 8.18 7.70 5.29 0.98 1.15 16 16 9.67 7.72 5.54 3.35
Net Working Capital (NWC)		 8.18 7.70 5.29 0.98 1.15 16 16 9.67 7.72 5.54 3.35
Net Nonoperating Expense (NNE)		 3.40 2.73 1.71 2.09 4.78 2.17 1.71 2.59 2.01 -0.02 1.73
Net Nonoperating Obligations (NNO)		 -4.21 -3.60 -2.64 -0.74 -1.52 -14 -15 -8.72 -5.74 -3.26 -0.31
Total Depreciation and Amortization (D&A)		 0.10 0.16 0.57 0.88 0.10 0.10 0.15 0.14 0.15 0.13 0.19
Debt-free, Cash-free Net Working Capital to Revenue		 41.99% 39.09% 23.54% 2.50% -4.38% 31.80% 10.40% 10.85% 17.94% 26.47% 24.89%
Debt-free Net Working Capital to Revenue		 86.19% 73.45% 46.91% 10.22% 13.73% 293.41% 153.68% 109.82% 78.53% 64.22% 37.29%
Net Working Capital to Revenue		 86.19% 73.45% 46.91% 10.22% 13.73% 288.33% 153.68% 109.82% 78.53% 64.22% 37.29%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.26) ($0.22) ($0.16) ($0.21) ($0.16) ($0.12) ($0.10) ($0.12) ($0.10) ($0.06) ($0.07)
Adjusted Weighted Average Basic Shares Outstanding		 21.43M 26.97M 32.70M 35.30M 45.74M 63.06M 68.83M 70.61M 72.78M 79.79M 82.06M
Adjusted Diluted Earnings per Share		 ($0.26) ($0.22) ($0.16) ($0.21) ($0.16) ($0.12) ($0.10) $0.00 $0.00 $0.00 ($0.07)
Adjusted Weighted Average Diluted Shares Outstanding		 21.43M 26.97M 32.70M 35.30M 45.74M 63.06M 68.83M 70.00M 76.60M 0.00 82.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 ($0.16) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 21M 30.68M 33.16M 40.86M 49.41M 66.56M 68.12M 70.00M 76.60M 0.00 80.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.14 -4.56 -3.66 -4.52 -2.80 -5.22 -5.16 -6.18 -4.97 -4.73 -3.99
Normalized NOPAT Margin		 -22.54% -43.50% -32.48% -46.99% -33.43% -95.95% -50.12% -70.17% -50.62% -54.81% -44.44%
Pre Tax Income Margin		 -32.22% -62.18% -46.36% -83.13% -91.27% -137.41% -69.08% -99.62% -71.04% -54.62% -63.76%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -412.21 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -288.55 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -413.39 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 -289.73 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Milestone Scientific

This table displays calculated financial ratios and metrics derived from Milestone Scientific's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 71,365,659.00 71,048,241.00 76,602,116.00 77,227,714.00 77,287,714.00 77,892,083.00 77,892,083.00 78,477,320.00 78,559,147.00 78,628,913.00 80,453,116.00
DEI Adjusted Shares Outstanding		 71,365,659.00 71,048,241.00 76,602,116.00 77,227,714.00 77,287,714.00 77,892,083.00 77,892,083.00 78,477,320.00 78,559,147.00 78,628,913.00 80,453,116.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.02 -0.03 -0.02 0.00 -0.02 -0.03 -0.03 -0.02 -0.01 -0.01 -0.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -7.06% 0.88% -13.43% -36.30% 22.07% -10.93% -0.73% 25.34% -6.11% 2.21% -3.15%
EBITDA Growth		 25.91% 1.64% -9.67% 110.47% 2.14% -3.12% -36.64% -712.16% 23.72% 48.74% 60.05%
EBIT Growth		 25.17% 1.74% -9.12% 108.90% 2.49% -3.17% -36.37% -832.53% 22.78% 47.13% 58.55%
NOPAT Growth		 25.17% 1.74% -9.12% -11.68% 2.49% -3.17% -36.37% 41.63% 22.78% 47.13% 58.55%
Net Income Growth		 25.66% 1.52% -9.19% 110.03% 1.01% -4.03% -38.46% -763.17% 21.03% 46.42% 57.89%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 50.00% 0.00% 50.00%
Operating Cash Flow Growth		 7.72% -14.33% 39.20% 176.56% 7.53% -21.33% 17.24% -325.12% 108.40% 85.04% 108.61%
Free Cash Flow Firm Growth		 -65.74% -89.29% 41.64% -14.78% 36.02% 26.82% 17.84% 31.59% 89.49% 60.68% 73.13%
Invested Capital Growth		 73.24% 75.98% 4.93% 19.65% 12.14% 13.31% -16.97% 18.64% -24.65% -2.90% -14.69%
Revenue Q/Q Growth		 -29.23% 9.78% -0.52% -17.57% 35.61% -19.90% 10.87% 4.08% 1.58% -12.80% 5.06%
EBITDA Q/Q Growth		 34.43% -32.73% 26.63% 116.39% -713.15% -39.86% 2.78% 26.57% 23.59% 6.03% 24.22%
EBIT Q/Q Growth		 33.85% -31.38% 25.99% 113.83% -824.90% -39.01% 2.18% 25.69% 23.59% 4.83% 23.30%
NOPAT Q/Q Growth		 33.85% -31.38% 25.99% -73.61% 42.24% -39.01% 2.18% 25.69% 23.59% 4.83% 23.30%
Net Income Q/Q Growth		 33.77% -32.56% 26.38% 115.52% -753.36% -39.31% 2.01% 25.64% 22.19% 5.49% 22.99%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -2.90% -18.29% 2.22% 164.33% -224.28% -55.20% 33.30% -75.00% 104.64% -376.53% 138.40%
Free Cash Flow Firm Q/Q Growth		 -8.47% -15.03% 51.37% -89.16% 39.54% -31.58% 45.40% -57.51% 90.71% -392.35% 62.69%
Invested Capital Q/Q Growth		 17.48% -4.20% 17.46% -9.49% 10.11% -3.20% -13.93% 29.33% -30.07% 24.74% -24.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 73.01% 66.78% 74.53% 76.13% 73.05% 75.05% 73.80% 69.62% 69.52% 72.97% 72.34%
EBITDA Margin		 -71.26% -86.16% -63.54% 12.63% -57.12% -99.74% -87.46% -61.70% -46.41% -50.02% -36.08%
Operating Margin		 -73.17% -87.57% -65.15% -96.04% -58.44% -101.43% -89.49% -63.90% -48.07% -52.46% -38.30%
EBIT Margin		 -73.17% -87.57% -65.15% 10.93% -58.44% -101.43% -89.49% -63.90% -48.07% -52.46% -38.30%
Profit (Net Income) Margin		 -71.68% -86.56% -64.06% 12.06% -58.13% -101.09% -89.35% -63.83% -48.89% -52.99% -38.85%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.97% 98.85% 98.33% 110.34% 99.45% 99.67% 99.84% 99.90% 101.72% 101.01% 101.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -268.54% -338.10% -165.86% -364.81% -144.35% -252.83% -220.92% -153.84% -128.84% -129.88% -116.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 -262.70% -330.20% -158.64% -400.53% -134.92% -239.37% -203.98% -139.08% -114.75% -111.13% -96.55%
Return on Net Nonoperating Assets (RNNOA)		 208.62% 264.90% 109.16% 287.07% 87.16% 155.57% 120.41% 74.04% 59.98% 45.90% 37.79%
Return on Equity (ROE)		 -59.92% -73.20% -56.70% -77.74% -57.19% -97.26% -100.51% -79.80% -68.87% -83.98% -78.47%
Cash Return on Invested Capital (CROIC)		 -320.85% -334.27% -198.97% -230.40% -197.70% -207.65% -190.38% -202.43% -171.77% -154.22% -138.47%
Operating Return on Assets (OROA)		 -55.49% -68.64% -52.28% 7.95% -47.69% -82.70% -75.43% -57.88% -43.66% -53.49% -40.00%
Return on Assets (ROA)		 -54.37% -67.85% -51.40% 8.78% -47.43% -82.43% -75.31% -57.82% -44.41% -54.03% -40.57%
Return on Common Equity (ROCE)		 -61.43% -74.09% -57.48% -78.95% -58.21% -97.26% -100.51% -79.80% -68.87% -83.98% -78.47%
Return on Equity Simple (ROE_SIMPLE)		 -96.75% 0.00% -95.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.05 -1.39 -1.03 -1.78 -1.03 -1.43 -1.40 -1.04 -0.79 -0.76 -0.58
NOPAT Margin		 -51.22% -61.30% -45.60% -96.04% -40.91% -71.00% -62.64% -44.73% -33.65% -36.72% -26.81%
Net Nonoperating Expense Percent (NNEP)		 -5.84% -7.90% -7.22% 35.72% -9.43% -13.47% -16.94% -14.77% -14.09% -18.75% -19.71%
Return On Investment Capital (ROIC_SIMPLE)		 - -17.29% -13.75% -22.38% -14.24% -24.51% -31.34% -25.10% -23.71% -20.92% -18.79%
Cost of Revenue to Revenue		 26.99% 33.22% 25.47% 23.87% 26.95% 24.95% 26.20% 30.38% 30.48% 27.03% 27.66%
SG&A Expenses to Revenue		 137.12% 145.99% 134.97% 154.72% 121.92% 165.24% 145.88% 130.45% 116.05% 123.90% 109.74%
R&D to Revenue		 8.28% 7.83% 4.19% 16.99% 9.23% 10.80% 16.53% 2.23% 0.69% 0.60% 0.00%
Operating Expenses to Revenue		 146.17% 154.35% 139.68% 172.17% 131.49% 176.48% 163.29% 133.52% 117.59% 125.43% 110.64%
Earnings before Interest and Taxes (EBIT)		 -1.51 -1.98 -1.47 0.20 -1.47 -2.04 -2.00 -1.48 -1.13 -1.08 -0.83
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -1.47 -1.95 -1.43 0.23 -1.44 -2.01 -1.95 -1.43 -1.10 -1.03 -0.78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 9.06 6.12 6.40 6.63 9.74 12.82 16.28 14.95 14.00 7.63 10.14
Price to Tangible Book Value (P/TBV)		 9.30 6.26 6.55 6.77 9.96 13.15 16.77 15.48 14.55 7.85 10.42
Price to Revenue (P/Rev)		 6.69 4.99 5.03 6.27 7.93 8.66 8.43 5.50 4.00 2.39 2.60
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 25.63 18.95 16.01 19.46 24.66 27.78 31.77 17.26 17.54 8.46 12.05
Enterprise Value to Revenue (EV/Rev)		 6.20 4.38 4.51 5.58 7.39 8.29 8.17 5.45 3.94 2.36 2.56
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.31 0.28 0.35
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.24 0.31 0.28 0.35
Financial Leverage		 -0.79 -0.80 -0.69 -0.72 -0.65 -0.65 -0.59 -0.53 -0.52 -0.41 -0.39
Leverage Ratio		 1.42 1.39 1.41 1.48 1.53 1.53 1.71 1.78 2.01 2.04 2.53
Compound Leverage Factor		 1.39 1.38 1.39 1.63 1.52 1.52 1.71 1.77 2.05 2.06 2.56
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.32% 23.88% 22.14% 25.93%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.32% 23.88% 22.14% 25.93%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 -3.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 103.62% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 80.68% 76.12% 77.86% 74.07%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.12 -0.12 -0.15 -0.18
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.08 0.06 0.09
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.12 -0.12 -0.15 -0.18
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 -0.17 -0.20 -0.25
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.12 0.08 0.12
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.16 -0.17 -0.20 -0.25
Altman Z-Score		 -3.87 -5.33 -6.86 -5.19 -4.00 -6.11 -9.84 -15.41 -17.24 -20.20 -20.07
Noncontrolling Interest Sharing Ratio		 -2.53% -1.22% -1.38% -1.56% -1.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.04 3.51 2.97 3.00 2.85 2.48 1.94 2.03 1.61 1.81 1.51
Quick Ratio		 1.59 2.04 1.56 1.60 1.42 1.00 0.62 0.52 0.41 0.44 0.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.06 -2.37 -1.15 -2.18 -1.32 -1.73 -0.95 -1.49 -0.14 -0.68 -0.25
Operating Cash Flow to CapEx		 0.00% -33,770.64% 0.00% 11,880.76% 0.00% -42,842.63% -77,307.44% -39,449.55% 1,312.18% -7,257.03% 5,321.20%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.76 0.78 0.80 0.73 0.82 0.82 0.84 0.91 0.91 1.02 1.04
Accounts Receivable Turnover		 11.66 19.53 12.04 14.32 15.51 21.90 14.52 16.86 14.06 15.19 16.14
Inventory Turnover		 0.94 0.85 0.78 0.58 0.55 0.49 0.47 0.51 0.49 0.50 0.52
Fixed Asset Turnover		 737.90 697.72 811.67 677.70 868.29 752.23 850.17 656.78 605.00 558.88 579.77
Accounts Payable Turnover		 1.73 2.02 1.83 1.32 1.33 1.68 0.97 1.18 1.02 1.19 0.87
Days Sales Outstanding (DSO)		 31.31 18.69 30.31 25.49 23.54 16.66 25.15 21.65 25.97 24.03 22.61
Days Inventory Outstanding (DIO)		 388.10 428.61 470.45 633.14 664.99 748.03 775.80 709.68 745.58 723.82 707.98
Days Payable Outstanding (DPO)		 211.14 180.79 199.55 276.59 273.62 217.37 378.14 308.29 357.24 306.11 420.36
Cash Conversion Cycle (CCC)		 208.28 266.51 301.21 382.04 414.91 547.32 422.81 423.03 414.30 441.74 310.23
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.37 2.27 2.67 2.42 2.66 2.57 2.22 2.87 2.00 2.50 1.89
Invested Capital Turnover		 5.24 5.52 3.64 3.80 3.53 3.56 3.53 3.44 3.83 3.54 4.34
Increase / (Decrease) in Invested Capital		 1.00 0.98 0.13 0.40 0.29 0.30 -0.45 0.45 -0.66 -0.07 -0.33
Enterprise Value (EV)		 61 43 43 47 66 72 70 49 35 21 23
Market Capitalization		 66 49 48 53 70 75 73 50 36 21 23
Book Value per Share		 $0.10 $0.11 $0.10 $0.10 $0.09 $0.07 $0.06 $0.04 $0.03 $0.04 $0.03
Tangible Book Value per Share		 $0.10 $0.11 $0.10 $0.10 $0.09 $0.07 $0.06 $0.04 $0.03 $0.03 $0.03
Total Capital		 6.99 8.01 7.46 7.95 7.22 5.83 4.46 4.14 3.35 3.61 3.08
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.80 0.80 0.80 0.80
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.80 0.80 0.80 0.80
Net Debt		 -4.62 -5.95 -5.01 -5.75 -4.78 -3.26 -2.25 -0.47 -0.55 -0.31 -0.39
Capital Expenditures (CapEx)		 -0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.07 1.76 2.17 1.92 2.17 2.28 1.93 2.59 1.73 2.23 1.30
Debt-free Net Working Capital (DFNWC)		 6.69 7.72 7.18 7.67 6.94 5.54 4.18 3.86 3.08 3.35 2.50
Net Working Capital (NWC)		 6.69 7.72 7.18 7.67 6.94 5.54 4.18 3.86 3.08 3.35 2.50
Net Nonoperating Expense (NNE)		 0.42 0.57 0.41 -2.00 0.43 0.61 0.60 0.44 0.36 0.33 0.26
Net Nonoperating Obligations (NNO)		 -4.62 -5.74 -4.79 -5.54 -4.56 -3.26 -2.25 -0.47 -0.55 -0.31 -0.39
Total Depreciation and Amortization (D&A)		 0.04 0.03 0.04 0.03 0.03 0.03 0.05 0.05 0.04 0.05 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 21.13% 17.94% 22.89% 22.74% 24.39% 26.47% 22.46% 28.50% 19.39% 24.89% 14.61%
Debt-free Net Working Capital to Revenue		 68.25% 78.53% 75.70% 91.03% 78.19% 64.22% 48.54% 42.53% 34.45% 37.29% 28.02%
Net Working Capital to Revenue		 68.25% 78.53% 75.70% 91.03% 78.19% 64.22% 48.54% 42.53% 34.45% 37.29% 28.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.02) ($0.03) ($0.02) $0.00 ($0.02) ($0.02) ($0.02) ($0.02) ($0.01) ($0.02) ($0.01)
Adjusted Weighted Average Basic Shares Outstanding		 73.73M 72.78M 79.74M 79.97M 79.97M 79.79M 81.85M 82.05M 82.32M 82.06M 85.04M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 ($0.01) $0.00 ($0.01)
Adjusted Weighted Average Diluted Shares Outstanding		 71.05M 76.60M 77.23M 79.97M 77.89M 79.79M 78.48M 78.56M 82.32M 82.06M 85.04M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 71.05M 76.60M 77.23M 77.29M 77.89M 0.00 78.48M 78.56M 78.63M 80.45M 88.08M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.05 -1.39 -1.03 -1.25 -1.03 -1.43 -1.40 -1.04 -0.79 -0.76 -0.58
Normalized NOPAT Margin		 -51.22% -61.30% -45.60% -67.23% -40.91% -71.00% -62.64% -44.73% -33.65% -36.72% -26.81%
Pre Tax Income Margin		 -71.68% -86.56% -64.06% 12.06% -58.13% -101.09% -89.35% -63.83% -48.89% -52.99% -38.85%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Milestone Scientific Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Milestone Scientific's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

The last 5 years of Milestone Scientific's net income performance:
  • 2021: -$6.88 million
  • 2022: -$8.77 million
  • 2023: -$6.98 million
  • 2024: -$4.71 million
  • 2025: -$5.72 million
Find out what analysts predict for Milestone Scientific in the coming months.

Milestone Scientific's total operating income in 2025 was -$5.70 million, based on the following breakdown:
  • Total Gross Profit: $6.41 million
  • Total Operating Expenses: $12.10 million

Over the last 10 years, Milestone Scientific's total revenue changed from $9.49 million in 2015 to $8.97 million in 2025, a change of -5.5%.

Milestone Scientific's total liabilities were at $4.99 million at the end of 2025, a 26.0% increase from 2024, and a 37.0% increase since 2015.

In the past 10 years, Milestone Scientific's cash and equivalents has ranged from $743.43 thousand in 2018 to $14.76 million in 2021, and is currently $1.11 million as of their latest financial filing in 2025.

Over the last 10 years, Milestone Scientific's book value per share changed from 0.48 in 2015 to 0.04 in 2025, a change of -92.5%.


Related Companies

Financial statements for NYSE:MLSS last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel